Literature DB >> 11280793

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

N Masumori1, T Z Thomas, P Chaurand, T Case, M Paul, S Kasper, R M Caprioli, T Tsukamoto, S B Shappell, R J Matusik.   

Abstract

Neuroendocrine (NE) cells may be involved not only in growth and differentiation of the normal prostate but also in carcinogenesis and progression of prostate adenocarcinoma (Pca), including development of androgen resistance. However, the exact pathophysiology of NE cells in Pca remains poorly understood. Here we describe a transgenic model of Pca with progressive NE differentiation. Seven lines of transgenic mice with the rat prostate-specific large probasin promoter linked to the SV40-large T antigen (Tag) that develop prostatic neoplasia have been established. In this study, one of the seven lines (12T-10) was characterized by examination of 52 mice aged from 2-12 months. With advancing age, low-grade prostatic intraepithelial neoplasia, high-grade prostatic intraepithelial neoplasia, microinvasion, invasive carcinoma, and poorly or undifferentiated carcinoma with NE differentiation appeared in the prostates in sequential order. Whereas Tag is expressed uniformly in prostate epithelium, only an increasing subset of cells in prostatic intraepithelial neoplasia showed NE differentiation by chromogranin immunostaining. Frankly invasive carcinoma developing subsequently showed occasional definitive glandular differentiation (adenocarcinoma) and particularly undifferentiated carcinoma with NE histological features similar to those observed in NE carcinomas in humans. The NE carcinomas occurred in the dorsolateral and ventral lobes and were generally androgen receptor negative. Twenty-one of 32 (66%) mice aged > or = 6 months and 15 of 17 (88%) mice aged > or = 9 months developed metastatic tumors, as confirmed by histology and/or Tag immunohistochemistry. Metastases occurred at the later time points, with metastasis to regional lymph nodes, liver, and lung being particularly common. Metastases showed histological features of NE differentiation, as confirmed by chromogranin immunostaining and electron microscopy. An athymic nude mouse that received a s.c. implant of a primary NE tumor developed Tag-positive metastatic tumors with similar NE differentiation. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry identified identical protein profiles between the primary NE tumor and lesions in the extraprostatic organs. Hence, in the 12T-10 large probasin promoter-Tag mouse, high-grade prostatic intraepithelial neoplasia develops progressively greater NE differentiation and progresses to invasive adenocarcinoma and NE carcinoma, with a high percentage of metastases. The predictable progression through these stages will allow testing of therapeutic interventions as well as possible further delineation of the role of NE cells in Pca progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.

Authors:  Zachary M Connelly; Shu Yang; Fenghua Chen; Yunshin Yeh; Nazih Khater; Renjie Jin; Robert Matusik; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

Review 2.  Simian virus 40 transformation, malignant mesothelioma and brain tumors.

Authors:  Fang Qi; Michele Carbone; Haining Yang; Giovanni Gaudino
Journal:  Expert Rev Respir Med       Date:  2011-10       Impact factor: 3.772

3.  Application of Gleason analogous grading system and flow cytometry DNA analysis in a novel knock-in mouse prostate cancer model.

Authors:  G Wu; Lei Yu; L Wang; H Wang; J W Xuan
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 4.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Prostatic intraepithelial neoplasia in genetically engineered mice.

Authors:  Jae-Hak Park; Judy E Walls; Jose J Galvez; Minjung Kim; Cory Abate-Shen; Michael M Shen; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 6.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

7.  A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype.

Authors:  Andrew J Syder; Sherif M Karam; Jason C Mills; Joseph E Ippolito; Habib R Ansari; Vidya Farook; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

8.  Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.

Authors:  Alfonso Calvo; Carlos Perez-Stable; Victor Segura; Raúl Catena; Elizabeth Guruceaga; Paul Nguewa; David Blanco; Luis Parada; Teresita Reiner; Jeffrey E Green
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

9.  The loss of TGF-beta signaling promotes prostate cancer metastasis.

Authors:  William H Tu; Tania Z Thomas; Naoya Masumori; Neil A Bhowmick; Agnieszka E Gorska; Yu Shyr; Susan Kasper; Tom Case; Richard L Roberts; Scott B Shappell; Harold L Moses; Robert J Matusik
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

10.  Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer.

Authors:  Yajun Yi; Srinivas Nandana; Thomas Case; Colleen Nelson; Tatjana Radmilovic; Robert J Matusik; Karen D Tsuchiya
Journal:  Mol Cytogenet       Date:  2009-09-26       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.